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     A 28 year old woman visited Mumbai, India in September 2010 and received many 
mosquito bites. Twelve days into her trip, she experienced a sudden onset of fever, chills, 
hyperpigmentation on the bridge of her nose, and severe joint pain in her wrists, ankles, 
and neck. She was treated for malaria and her fever resolved after three days with no 
recurrence (Schwartz, Giga, & Boggild, 2014).   
     After her recovery from acute illness, she still experienced considerable joint pain and 
restricted range of motion in her wrists, neck, and ankles. She was referred to a tropical 
disease unit two and a half months after her initial symptoms because of her persistent 
polyarthritis and minimal pain relief with the use of nonsteroidal anti-inflammatory drug, 
celecoxib. On physical examination, her vital signs were normal with no 
lymphadenopathy, hepatosplenomegaly, or joint effusions. Her complete blood count 
was normal with the exception of mildly elevated eosinophils (Schwartz et al, 2014). 
     Serologic studies revealed nonreactive results for rickettsia and an elevated titer to 
chikungunya immunoglobulin G (IgG) antibodies. Dengue IgG antibodies were reactive, 
but immunoglobulin M (IgM) antibodies were nonreactive. Because of her persistent 
arthralgia and nonreactive dengue IgM antibodies, it was concluded that the dengue IgG 
antibodies were a false-positive. She was diagnosed with chikungunya fever and was 
prescribed ibuprofen and physical therapy for treatment. Her arthralgia and range of 
motion improved over 18 months, but she still had not returned to her baseline after two 
years post-infection (Schwartz et al, 2014). 
 
           The Chikungunya virus (CHIKV) has 
spread like a wildfire in the Americas. Since 
its emergence in Sub-Saharan Africa as 
early at the 18th century, CHIKV has caused 
many isolated outbreaks in Africa, 
Southeast Asia, and Australia. Over the last 
decade, the vector-borne disease has 
inflicted millions of people on islands in the 
Indian Ocean, India, and now the Americas 
with the aid of viral mutations and 
international travel (Weaver and Lecuit, 
2015).  
     The first case of local CHIKV 
transmission in the Western Hemisphere 
was fairly recent. On the island of St. 
Martin in October 2013, an individual 
carrying an Asian strain of CHIKV was bitten 
by a local mosquito. This mosquito (A. 
aegypti) became a local carrier of the 
disease. A. aegypti can be found in the 
Caribbean, Central America, much of South 
America, and the southeastern United 
States. There are over 1.2 million reported 
cases in the Americas from 2013 to March 
2015 (Gaines, 2015). Recently, there have 
been 11 CHIKV cases in Florida which were 
transmitted by local mosquitos. Further 
spread of the virus throughout the 
Americas is expected (Weaver & Lecuit, 
2015). If a single gene mutation on the 
envelope protein occurs (which has 
happened on La Reunion Island), it could 
significantly boost the spread of the virus 
via another mosquito, A. albopictus. A. 
albopictus inhabits much of the United 
States including Ohio (Miner et al., 2015).  
     Advanced practice nurses (APN) should 
be aware of the clinical signs and 
symptoms, pathophysiology, and the 
implications for nursing care of CHIKV 
because of its recent rapid spread in the 
Western Hemisphere. The Centers for 
Disease Control and Prevention (CDC) are 
expected to add the virus to the list of 
notifiable conditions this year (Lindsey et 
al., 2015).  
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     Chikungunya is a vector-borne virus and is spread to humans by the bite of infected A. 
aegypti and A. albopictus mosquitos.  Humans are the “primary amplifying host” for CHIKV 
because mosquitoes become infected when they bite an infected human during their first 
week of illness and viremia. There are also maternal-fetal and bloodborne transmission cases 
(Staples & Fisher, 2015).  Infected mosquitoes are found in tropical and sub-tropical locations 
around the world, and most recently, the Americas. The virus is expected to spread 
throughout the Americas similar to the current distribution of the dengue virus (Coffey, 
Failloux, & Weaver, 2014).  
     CHIKV is an enveloped, single-stranded- RNA alphavirus. The virus replicates in fibroblasts 
of the dermis, then disseminated via the bloodstream to the liver, muscle, lymphoid tissue, 
choroid plexus, and joints. CHIKV can be found mostly in skin, muscle, and joint fibroblasts, 
but are also within the epithelial and endothelial layers of many organs such the liver and 
spleen. Cells that are infected with CHIKV rapidly undergo apoptosis. The incubation period 
of CHIKV is about 2-4 days with no prodromal phase. The onset of acute symptoms is sudden. 
The acute phase lasts a few days to a couple of weeks. There is a strong and immediate 
innate immune response, mainly by interferons and pro-inflammatory cytokines. Acute 
infection is also associated with transient lymphopenia and neutropenia (Schwartz & Albert, 
2010). The adaptive immune (primarily IgG and IgM antibodies) response can be identified 
one week after the onset of symptoms. IgG antibodies will persist for years as protection 
from recurrence (Schwartz et al., 2014).  Complications from acute illness include 
encephalitis especially in neonates and children, as well as cardiovascular disease, hepatitis, 
renal disease, pneumonia, respiratory failure, and hemorrhagic disease. The highest 
mortality from CHIKV is in neonates, people with underlying medical conditions, and the 
elderly. The fatality rate is estimated to be 1 in 1000 (Essackjee, Goorah, Ramchurn, 
Cheeneebash, & Walker-Bone, 2013). 
     Many CHIKV patients experience a chronic disease phase. The hallmark symptom of this 
phase is persistent arthralgia or arthritis which can last for months to years (Schwartz & 
Albert, 2010). The joint pain was presumed to be the result of an immune-mediated response 
similar to that of rheumatoid arthritis, but is not well understood.  In addition, macrophages 
and monocytes are involved in the clearance of viral debris which triggers a pro-
inflammatory response in the joints. Researchers do not know whether persistent CHIKV 
replication or remaining CHIKV antigens or both are responsible for the immune response 
(Weaver & Lecuit, 2015). 
  
     Understanding the pathophysiology of 
CHIKV is important when determining 
how to prevent the spread of disease and 
also when diagnosing, and treating the 
disease. Local authorities can prevent 
CHIKV by fogging the mosquitoes and by 
averting standing water. Understanding 
the pathophysiology allows the 
practitioner to order the appropriate 
diagnostic tests and predict the course of 
events in the disease process. The 
significance of comprehending the 
pathophysiology of CHIKV is most 
apparent in the development of 
treatments and a vaccine. Treatments 
cannot be developed if researchers and 
providers do not understand what is 
happening at a cellular level. Further 
research regarding the cause of the 
chronic disease is needed in order to treat 
this complication. 
 
• The acute phase involves a sudden 
onset of high fever and joint pain. 
  
• Headache, myalgia, photophobia, 
diarrhea, vomiting, nausea, 
hyperpigmentation, mucosal and 
dermal lesions  
 
• 40-50% of cases develop a 
maculopapular rash.   
 
• 90% will experience severe and 
often debilitating joint pain. The 
pain is usually bilateral and 
symmetrical in the hands, wrists, 
and ankles as well as larger joints 
such as the elbows, knees, and 
shoulders (Thiberville et al, 2013).  
 
• There are some “silent” cases where 
no signs and symptoms are 
detected (Schwartz & Albert, 2010).  
 
• The chronic phase involves 
persistent arthralgia in multiple 
joints. Studies vary on the 
proportion of patients who fully 
recover after acute illness and those 
that exhibit chronic symptoms.  
 
• CHIKV can cause long-term joint 
pain and disability similar to that of 
rheumatoid arthritis. The elderly 
and females are at a greater risk for 
this condition (Essackjee et al., 
2013). 
 
• Due to the increased incidence of 
CHIKV in the Americas and 
increases in international travel 
and globalization, more patients 
infected with CHIKV are 
presenting to providers in the 
United States.  
 
• CHIKV is often mistaken for 
dengue fever and sometimes 
malaria, so familiarity with the 
signs and symptoms of CHIKV is 
important. Dengue fever patients 
frequently present with 
hemorrhagic symptoms whereas 
patients with CHIKV will usually 
exhibit long lasting and 
debilitating joint pain (Tither, 
2014).  
 
• There is no drug or vaccine to 
protect anyone from CHIKV, so 
patients should be counseled to 
use bug spray, protective clothing, 
and mosquito nets as protection 
from mosquito bites.  
 
• If a patient presents with a 
possible infectious disease, always 
inquire about travel history and 
refer to an infectious disease 
specialist for treatment if needed. 
 
• Refer to the Centers for Disease 
Control and Prevention (CDC) 
traveler’s website for the most up-
to-date information on CHIKV 
(Tither, 2014). 
  
• CHIKV will soon have CDC 
reporting requirements (Moore, 
2015). 
     CHIKV is now a global vector-borne 
virus affecting 1.2 million people in the 
Americas alone. 2500 cases were 
reported in the United States, mostly 
from recent travelers in 2014 (Gaines, 
2015). The CDC provides the greatest 
amount of resources to providers 
regarding updates on the spread of the 
disease and prevention. Nurse 
practitioners need to be aware of the 
pathophysiology and signs and 
symptoms, and prevention of CHIKV in 
order to protect and treat patients 
properly. Pre-travel counseling about 
mosquito bite prevention is the best 
way to protect people from CHIKV in 
this globalized world. 
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